We propose that ppCT leader sequence-derived peptides constitute promising T cell targets permitting CTL to eradicate tumours with impaired antigen processing and presenting machinery (APM) and thus overcome tumour escape from CD8 T cell immunity. This evidence concerns the gene CD8A and neoplasm.